PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
November 07, 2023 08:55 ET
|
PharmAla Biotech
PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments
PharmAla Receives First Office Action for PharmAla-1 PCT Filing
September 25, 2023 08:55 ET
|
PharmAla Biotech
PharmAla has recieved a positive First Office Action on its novel P-1 Molecule from the Patent Cooperation Treaty
PharmAla Begins Trading on OTCQB
September 06, 2023 08:55 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF), a biotechnology company focused on the...
PharmAla Ships MDMA to Mind Medicine Australia and Orygen Institute
August 10, 2023 08:30 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
July 31, 2023 08:30 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, July 31, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
July 20, 2023 09:07 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
Cortexa Makes First Drug Order for Australian Commercial Market
July 04, 2023 08:55 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, July 04, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PharmAla Biotech Receives Export Permit to Ship GMP LaNeo MDMA to the University of Sydney
June 16, 2023 09:00 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, June 16, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF, a biotechnology company focused on the research,...
PharmAla Biotech announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000
June 12, 2023 20:07 ET
|
PharmAla Biotech
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 12, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (the...
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
June 09, 2023 15:48 ET
|
PharmAla Biotech
Approved Study to Examine Tolerability of MDMA in Schizophrenia at UCLA VANCOUVER, British Columbia, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE:...